InnoCare Pharma Limited (9969.HK)
HKD 6.1
(0.16%)
HKD 6.1
(0.16%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 738.53 Million | 625.4 Million | 1.04 Billion | 1.36 Million | 1.24 Million | 1.61 Million |
| Cost of Revenue | 128.43 Million | 143.39 Million | 65.66 Million | - | - | - |
| Gross Profit | 610.1 Million | 482 Million | 977.36 Million | 1.36 Million | 1.24 Million | 1.61 Million |
| Operating Expenses | 1.26 Billion | 1.21 Billion | 1.14 Billion | 495.91 Million | 251.87 Million | 150.26 Million |
| Selling, General and Administrative Expenses | 551.28 Million | 489.61 Million | 344.66 Million | 113.14 Million | 36.12 Million | 6.36 Million |
| Research and Development Expenses | 757.25 Million | 639.13 Million | 721.58 Million | 402.77 Million | 213.12 Million | 149.72 Million |
| Other Expenses | -47.27 Million | 84.39 Million | 74.75 Million | -20 Million | 2.62 Million | -415.78 Million |
| Cost and Expenses | 1.38 Billion | 1.35 Billion | 1.2 Billion | 495.91 Million | 251.87 Million | 150.26 Million |
| Operating Income | -651.15 Million | -891.62 Million | -24.25 Million | -464.89 Million | -2.15 Billion | -148.64 Million |
| Interest Expense | 35.06 Million | 17.04 Million | 2.64 Million | 1.13 Million | 938 Thousand | 1.44 Million |
| Income Tax Expense | 1.42 Million | -22.07 Million | 46.55 Million | -1.09 Million | -11.79 Million | -403.92 Million |
| Earnings before Tax | -644.2 Million | -893.72 Million | -20.12 Million | -464.26 Million | -2.15 Billion | -554.02 Million |
| Net Income | -631.26 Million | -871.65 Million | -66.67 Million | -463.16 Million | -2.13 Billion | -549.95 Million |
| Earnings Per Share Basic | -0.37 | -0.59 | -0.05 | -0.48 | -1.71 | -0.44 |
| Earnings Per Share Diluted | -0.37 | -0.59 | -0.05 | -0.48 | -1.71 | -0.44 |
| Weighted Average Shares Outstanding | 1.7 Billion | 1.47 Billion | 1.36 Billion | 967.57 Million | 1.25 Billion | 1.25 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.7 Billion | 1.47 Billion | 1.36 Billion | 967.57 Million | 1.25 Billion | 1.25 Billion |
| Gross Margin | 0.83 | 0.77 | 0.94 | 1.00 | 1.00 | 1.00 |
| EBIT Margin | -0.70 | -1.32 | 0.01 | -332.43 | -1719.42 | -339.22 |
| Profit Margin | -0.85 | -1.39 | -0.06 | -339.56 | -1714.96 | -340.11 |
| EBITDA | -516.55 Million | -808.27 Million | 16.23 Million | -453.43 Million | -2.14 Billion | -547.18 Million |
| Earnings Before Tax Margin | -0.88 | -1.43 | -0.02 | -340.83 | -1726.69 | -91.93 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 253.91 Million | 165.82 Million | 201.17 Million | 738.53 Million | 159.81 Million | 188.16 Million |
| Cost of Revenue | 35.84 Million | 24.29 Million | 27.55 Million | 128.43 Million | 24.8 Million | 33.17 Million |
| Gross Profit | 218.06 Million | 141.53 Million | 173.61 Million | 610.1 Million | 135 Million | 154.98 Million |
| Operating Expenses | 354.64 Million | 287.19 Million | 308.14 Million | 1.25 Billion | 344.23 Million | 352.47 Million |
| Selling, General and Administrative Expenses | -14.17 Million | 131.94 Million | -143.11 Million | - | 273.24 Million | -873.52 Thousand |
| Research and Development Expenses | 243.09 Million | 177.72 Million | 201.45 Million | - | 191.58 Million | 217.17 Million |
| Other Expenses | -52.41 Million | 31 Thousand | -185.07 Million | -146.29 Million | 241.63 Million | -202.85 Million |
| Cost and Expenses | 390.49 Million | 311.48 Million | 335.69 Million | 1.38 Billion | 369.04 Million | 385.64 Million |
| Operating Income | -133.18 Million | -161.85 Million | -192.98 Million | -708.13 Million | -62.8 Million | -218.69 Million |
| Interest Expense | 5.28 Million | 5.17 Million | -870.4 Thousand | 35.03 Million | 15.55 Million | 9.98 Million |
| Income Tax Expense | 28.97 Thousand | 20.00 | 1.42 Million | 1.42 Million | -1.14 Million | -5.15 Million |
| Earnings before Tax | -122.26 Million | -145.66 Million | -104.91 Million | -644.2 Million | -110.1 Million | -414.95 Million |
| Net Income | -119.43 Million | -142.4 Million | -100.09 Million | -631.26 Million | -108.95 Million | -409.8 Million |
| Earnings Per Share Basic | -0.07 | -0.08 | -0.06 | - | -0.06 | -0.19 |
| Earnings Per Share Diluted | -0.07 | -0.08 | -0.06 | - | -0.06 | -0.19 |
| Weighted Average Shares Outstanding | 1.76 Billion | 1.78 Billion | 1.68 Billion | 1.7 Billion | 1.77 Billion | 2.12 Billion |
| Weighted Average Shares Outstanding (Diluted) | 1.76 Billion | 1.78 Billion | 1.68 Billion | 1.7 Billion | 1.77 Billion | 2.12 Billion |
| Gross Margin | 0.86 | 0.85 | 0.86 | 0.83 | 0.84 | 0.82 |
| EBIT Margin | -0.52 | -0.89 | -0.59 | - | -0.39 | -2.23 |
| Profit Margin | -0.47 | -0.86 | -0.50 | -0.85 | -0.68 | -2.18 |
| EBITDA | -133.18 Million | -147.36 Million | -118.2 Million | - | -62.8 Million | -419.71 Million |
| Earnings Before Tax Margin | -0.52 | -0.98 | -0.96 | -0.96 | -0.39 | -1.16 |
CMTUF
NXR
0K0X
4919
PKOH
NOS